Generic drugmakers Teva and Sandoz make major push to biosimilars

Nov 22 (Reuters) - Generic drug makers Teva Pharmaceutical Industries and Sandoz say they are planning a significant ramp-up in production of biosimilars – copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer – aiming to increase their share of an expanding market.More than 55 brand-name blockbuster biologic drugs, each with peak annual sales above $1 billion, are due to…